Intra-Cellular Therapies shares plunge 68 percent after study results on a schizophrenia drug trial. CNBC's Seema Mody reports. » Read More
Regulators said they have told Mylan that it should be paying higher rebates on sales of EpiPens through Medicaid. » Read More
CNBC's Meg Tirrell reports the latest on Gilead. Geoff Porges, Leerink Partners managing director and senior biotech analyst, weighs in. » Read More
Shares of Ligand Pharmaceuticals plunged 12 percent Tuesday after Amgen said its multiple myeloma drug, Kyprolis, did not outperform Takeda Pharmaceutical's Velcade in a late-stage study.
» Read More
Get the best of CNBC in your inbox
Dan Mangan is a reporter covering health care for CNBC.com.
Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.
Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.